Sosei Group Corporation
TSE:4565.T
1,173 (JPY) • At close November 5, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Sosei Group Corporation |
Symbool | 4565.T |
Munteenheid | JPY |
Prijs | 1,174 |
Beurswaarde | 105,543,947,752 |
Dividendpercentage | 0% |
52-weken bereik | 1,125 - 1,826 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Christopher Cargill |
Website | https://soseiheptares.com |
An error occurred while fetching data.
Over Sosei Group Corporation
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of HTL0022562, a calcitonin gene related peptide antagonist, which is in Phase I clinical
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (JPY)
Cijfers zijn in miljoenen (JPY)